Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026

Curis (NASDAQ: CRIS) will report its third quarter 2026 financial and operating results on November 12, 2026, at 4:00 p.m. ET.

Rhea-AI Summary

Curis (NASDAQ: CRIS) will report its third quarter 2026 financial and operating results on November 12, 2026, at 4:00 p.m. ET.

Management will host a conference call and simultaneous webcast that day at 4:30 p.m. ET. A replay will be available on the Curis website.

Key Terms

irak4, flt3 inhibitor

2 terms

irak4 medical

"small molecule IRAK4 and FLT3 inhibitor"

IRAK4 is a protein in immune-system cells that acts like a control knob for inflammation signals, helping the body detect and respond to infections. Drugs that block IRAK4 can dial down excessive inflammation, so IRAK4 is an important target for developing treatments for autoimmune diseases and some cancers; progress or setbacks in IRAK4 drug programs can materially affect the prospects and valuation of companies working in those areas.

flt3 inhibitor medical

"IRAK4 and FLT3 inhibitor"

A FLT3 inhibitor is a drug that blocks the action of the FLT3 protein, which can send strong growth signals in certain blood cancers; when FLT3 is abnormal, it acts like a stuck accelerator pedal that makes cancer cells multiply. Investors watch FLT3 inhibitors because their success in clinical trials and approval can drive sales growth, affect company valuations and partnerships, and change the competitive landscape and regulatory risk in cancer treatment markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., Nov. 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its third quarter 2026 financial and operating results on Thursday, November 12, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET.

Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com.

About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company's monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948). For more information, visit Curis's website at www.curis.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-third-quarter-2026-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-12-2026-302931358.html

SOURCE Curis, Inc.